GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » EBITDA Margin %

3SBio (HKSE:01530) EBITDA Margin % : 26.56% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is 3SBio EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. 3SBio's EBITDA for the six months ended in Dec. 2023 was HK$1,171 Mil. 3SBio's Revenue for the six months ended in Dec. 2023 was HK$4,410 Mil. Therefore, 3SBio's EBITDA margin for the quarter that ended in Dec. 2023 was 26.56%.


3SBio EBITDA Margin % Historical Data

The historical data trend for 3SBio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio EBITDA Margin % Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.34 25.43 35.48 40.08 32.31

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.95 43.64 37.17 38.44 26.56

Competitive Comparison of 3SBio's EBITDA Margin %

For the Biotechnology subindustry, 3SBio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where 3SBio's EBITDA Margin % falls into.



3SBio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

3SBio's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=2762.451/8548.908
=32.31 %

3SBio's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1171.391/4410.231
=26.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio  (HKSE:01530) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


3SBio EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of 3SBio's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (HKSE:01530) Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Lou Jing 2305 Beneficiary of a trust
Jpmorgan Chase & Co. 2502 Approved lending agent
Hsbc Holdings Plc 2302 Custodian
Citic Securities Company Limited 2201 Interest of corporation controlled by you
Citron Pe Associates, L.p. 2201 Interest of corporation controlled by you
Citron Pe Funds Limited 2201 Interest of corporation controlled by you
Citron Pe Holdings Limited 2201 Interest of corporation controlled by you
Cpechina Fund, L.p. 2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited 2101 Beneficial owner
Tmf (cayman) Ltd. 2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited

3SBio (HKSE:01530) Headlines

No Headlines